{"id":8771,"date":"2026-09-28T17:29:46","date_gmt":"2026-09-28T14:29:46","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=8771"},"modified":"2026-09-28T17:29:50","modified_gmt":"2026-09-28T14:29:50","slug":"rinvatercept-phase-2-dmd-trial-first-patient","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/rinvatercept-phase-2-dmd-trial-first-patient\/","title":{"rendered":"Keros Therapeutics, Faz 2 Rinvatercept \u00c7al\u0131\u015fmas\u0131nda \u0130lk Hastaya Doz Verdi"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Keros Therapeutics, Duchenne kas distrofisi (DMD) i\u00e7in deneysel bir tedavi olan Rinvatercept&#039;in geli\u015ftirilmesinde \u00f6nemli bir ad\u0131m att\u0131\u011f\u0131n\u0131 duyurdu. <strong>\u015eirket, 28 Eyl\u00fcl 2026&#039;da, DMD hastalar\u0131nda Rinvatercept&#039;in de\u011ferlendirildi\u011fi Faz 2 klinik denemesinde ilk hastaya doz uyguland\u0131\u011f\u0131n\u0131 bildirdi.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eirket, denemeden elde edilecek ilk verilerin 2027 y\u0131l\u0131n\u0131n ilk yar\u0131s\u0131nda a\u00e7\u0131klanmas\u0131n\u0131 bekliyor. Ancak Rinvatercept hala ara\u015ft\u0131rma a\u015famas\u0131nda oldu\u011fundan, denemenin amac\u0131 tedavinin DMD hastalar\u0131 i\u00e7in g\u00fcvenli, tolere edilebilir ve potansiyel olarak faydal\u0131 olup olmad\u0131\u011f\u0131n\u0131 belirlemektir. Hen\u00fcz DMD i\u00e7in onaylanm\u0131\u015f bir tedavi de\u011fildir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Rinvatercept Nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Rinvatercept, kas ve kemik b\u00fcy\u00fcmesinde rol oynayan biyolojik sinyalleri etkilemek \u00fczere tasarlanm\u0131\u015ft\u0131r. Ligand tuza\u011f\u0131 ad\u0131 verilen bir tedavi t\u00fcr\u00fcd\u00fcr. \u0130la\u00e7, kas ve kemik b\u00fcy\u00fcmesini s\u0131n\u0131rlayabilen miyostatin ve aktivin A adl\u0131 iki proteinin etkilerini bloke etmek \u00fczere tasarlanm\u0131\u015ft\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Keros'a g\u00f6re, bu sinyallerin bloke edilmesi kas yenilenmesini desteklemeye, kas boyutunu ve g\u00fcc\u00fcn\u00fc art\u0131rmaya, fibrozis ve iltihab\u0131 azaltmaya, ya\u011f birikimini azaltmaya ve kemik sa\u011fl\u0131\u011f\u0131n\u0131 iyile\u015ftirmeye yard\u0131mc\u0131 olabilir. Bu etkiler, DMD'de Rinvatercept'in incelenmesinin bilimsel gerek\u00e7esinin bir par\u00e7as\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fcler \u00fczerinde yap\u0131lan \u00f6nceki Faz 1 ara\u015ft\u0131rmalar\u0131, kas k\u00fctlesi, ya\u011f k\u00fctlesi ve kemik mineral yo\u011funlu\u011fu ile ilgili g\u00f6zlemler de ortaya koymu\u015ftur. Bu bulgular, program\u0131n Faz 2 klinik geli\u015ftirme a\u015famas\u0131na ge\u00e7mesinin temelini olu\u015fturmu\u015ftur.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Faz 2 DMD Klinik Ara\u015ft\u0131rmas\u0131 Neler \u0130\u00e7erecek?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>NCT07704099 olarak tan\u0131mlanan Faz 2 \u00e7al\u0131\u015fmas\u0131, a\u00e7\u0131k etiketli, \u00e7oklu kohortlu bir klinik \u00e7al\u0131\u015fmad\u0131r. \u00c7al\u0131\u015fman\u0131n temel amac\u0131, DMD hastalar\u0131nda Rinvatercept&#039;in g\u00fcvenli\u011fini ve tolerans\u0131n\u0131 de\u011ferlendirmektir.<\/strong> Devam\u0131n\u0131 oku: <a href=\"https:\/\/dmdwarrior.com\/clinical-trials\/tr\/safety-and-efficacy-of-ker-065-in-participants-with-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07704099<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c7al\u0131\u015fma, hastal\u0131\u011f\u0131n farkl\u0131 a\u015famalar\u0131ndaki hastalar\u0131 kapsayacak \u015fekilde tasarlanm\u0131\u015ft\u0131r; bunlar aras\u0131nda ge\u00e7 d\u00f6nemde y\u00fcr\u00fcyebilen ve erken d\u00f6nemde y\u00fcr\u00fcyemeyen hastalar da bulunmaktad\u0131r. Ara\u015ft\u0131rmac\u0131lar ayr\u0131ca tedavinin v\u00fccudu nas\u0131l etkiledi\u011fini anlamak i\u00e7in \u00e7e\u015fitli di\u011fer alanlar\u0131 da inceleyeceklerdir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bunlar aras\u0131nda, bir ilac\u0131n v\u00fccutta nas\u0131l hareket etti\u011fini a\u00e7\u0131klayan farmakokinetik ve ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin tedaviye tepki verip vermedi\u011fini g\u00f6sterebilen ila\u00e7 kar\u015f\u0131t\u0131 antikorlar yer almaktad\u0131r. Ara\u015ft\u0131rmac\u0131lar ayr\u0131ca v\u00fccut kompozisyonunu ve iskelet kas\u0131, motor fonksiyon, kalp ve akci\u011ferleri i\u00e7eren fonksiyonel \u00f6l\u00e7\u00fcmleri de de\u011ferlendireceklerdir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu geni\u015f kapsaml\u0131 yakla\u015f\u0131m \u00f6nemlidir \u00e7\u00fcnk\u00fc DMD sadece y\u00fcr\u00fcme yetene\u011fini etkilemekle kalmaz. Kas zay\u0131fl\u0131\u011f\u0131 solunum fonksiyonunu, kalp sa\u011fl\u0131\u011f\u0131n\u0131, v\u00fccut kompozisyonunu ve genel fiziksel i\u015flevi de etkileyebilir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Bu Klinik Deneme Neden \u00d6nemli?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">DMD, kas g\u00fc\u00e7s\u00fczl\u00fc\u011f\u00fcne neden olan ve v\u00fccudun bir\u00e7ok sistemini etkileyen ilerleyici bir genetik hastal\u0131kt\u0131r. Bir\u00e7ok tedavi yakla\u015f\u0131m\u0131 mevcut veya geli\u015ftirilme a\u015famas\u0131nda olsa da, ara\u015ft\u0131rmac\u0131lar hastal\u0131\u011f\u0131n ek y\u00f6nlerini ele alabilecek terapileri ara\u015ft\u0131rmaya devam etmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Rinvatercept, distrofin \u00fcretimini eski haline getirmeyi ama\u00e7layan tedavilerden farkl\u0131 bir yakla\u015f\u0131m\u0131 temsil eder. Bunun yerine, kas ve kemik biyolojisinde yer alan biyolojik yollar\u0131 de\u011fi\u015ftirmeyi hedefler.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Faz 2 \u00e7al\u0131\u015fmas\u0131, \u00f6nceki ara\u015ft\u0131rmalarda g\u00f6zlemlenen biyolojik etkilerin DMD&#039;li ki\u015filerde anlaml\u0131 sonu\u00e7lara d\u00f6n\u00fc\u015f\u00fcp d\u00f6n\u00fc\u015fmeyece\u011fi konusunda \u00f6nemli bilgiler sa\u011flayacakt\u0131r. Bununla birlikte, etkinli\u011fi hakk\u0131nda sonu\u00e7lara var\u0131lmadan \u00f6nce sonu\u00e7lar\u0131n dikkatlice de\u011ferlendirilmesi gerekecektir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DMD tedavi s\u00fcrecini takip eden aileler i\u00e7in bir sonraki \u00f6nemli d\u00f6n\u00fcm noktas\u0131, 2027 y\u0131l\u0131n\u0131n ilk yar\u0131s\u0131nda beklenen klinik veriler olacakt\u0131r. Bu sonu\u00e7lar elde edilene kadar, Rinvatercept, yerle\u015fik bir DMD tedavisi yerine deneysel bir tedavi olarak de\u011ferlendirilmelidir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Klinik deneme bilgileri, \u00e7al\u0131\u015fma ilerledik\u00e7e de\u011fi\u015febilir; bu nedenle hastalar ve aileleri her zaman resmi deneme kay\u0131tlar\u0131n\u0131 kontrol etmeli ve klinik denemeye kat\u0131l\u0131m konusunu sa\u011fl\u0131k ekipleriyle g\u00f6r\u00fc\u015fmelidir.<\/p>","protected":false},"excerpt":{"rendered":"<p>Keros Therapeutics has announced an important step in the development of Rinvatercept, an investigational treatment for Duchenne muscular dystrophy (DMD). The company reported on September 28, 2026, that the first patient has been dosed in its Phase 2 clinical trial evaluating Rinvatercept in people with DMD. The company expects initial data from the trial in [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":8772,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[137,337,336,914,915],"class_list":["post-8771","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trial","tag-ker-065","tag-keros-therapeutics","tag-phase-2","tag-rinvatercept"],"subtitle":"Keros Therapeutics, Duchenne kas distrofisi (DMD) i\u00e7in Rinvatercept'in Faz 2 denemesine ilk hastay\u0131 dahil etti. \u00c7al\u0131\u015fma, g\u00fcvenli\u011fi ve kas, kalp ve akci\u011fer fonksiyonlar\u0131 \u00fczerindeki potansiyel etkilerini de\u011ferlendirecektir. \u0130lk verilerin 2027'de elde edilmesi bekleniyor.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=8771"}],"version-history":[{"count":2,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8771\/revisions"}],"predecessor-version":[{"id":8774,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8771\/revisions\/8774"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/8772"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=8771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=8771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=8771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}